
Modified Cochrane Common Mental Disorders Depression Anxiety and Neurosis Group Scores for Included Trials
Item | Aggarwal 2018 | Alianova 2019 | Parkman 2023 | Tack 2012 | Taghvaei 2021 | |
---|---|---|---|---|---|---|
1 | Objectives | 2 | 2 | 2 | 2 | 2 |
2 | Adequate sample size | 0 | 0 | 0 | 0 | 0 |
3 | Appropriate duration of follow-up | 0 | 0 | 0 | 0 | 0 |
4 | Power calculation | 2 | 0 | 2 | 2 | 1 |
5 | Method of allocation | 2 | 1 | 2 | 1 | 2 |
6 | Concealment of allocation | 0 | 1 | 2 | 0 | 2 |
7 | Clear description of treatment | 1 | 1 | 2 | 1 | 1 |
8 | Blinding of subjects | 1 | 0 | 1 | 1 | 1 |
9 | Source of subjects and recruitment | 0 | 1 | 1 | 0 | 1 |
10 | Use of diagnostic criteria | 1 | 1 | 0 | 2 | 2 |
11 | Record of exclusion criteria | 1 | 1 | 1 | 1 | 1 |
12 | Description of sample demographics | 0 | 1 | 2 | 0 | 2 |
13 | Blinding of assessor | 1 | 0 | 1 | 1 | 1 |
14 | Assessment of compliance | 2 | 0 | 2 | 0 | 0 |
15 | Details on side-effects | 2 | 0 | 2 | 0 | 1 |
16 | Record of withdrawals | 2 | 0 | 2 | 2 | 2 |
17 | Outcome measures | 2 | 2 | 2 | 2 | 2 |
18 | Comparability and adjustment for differences | 2 | 2 | 2 | 2 | 2 |
19 | Intention-to-treat analysis | 2 | 0 | 2 | 0 | 0 |
20 | Presentation of results | 2 | 1 | 2 | 2 | 2 |
21 | Appropriate statistical analysis | 1 | 1 | 2 | 1 | 1 |
22 | Conclusions justified | 2 | 2 | 2 | 2 | 2 |
23 | Declaration of interests | 2 | 0 | 2 | 2 | 2 |
Total score (/46) | 30 | 17 | 36 | 24 | 30 | |
65% | 37% | 78% | 52% | 65% |